N-Phenylbenzylamine

CAS No. 103-32-2

N-Phenylbenzylamine( —— )

Catalog No. M10161 CAS No. 103-32-2

A series of benzylaniline hydrochlorides as potential cytotoxic and antimitotic agents acting by inhibition of tubulin polymerization.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 34 In Stock
10MG 45 In Stock
25MG 61 In Stock
50MG 98 In Stock
100MG 129 In Stock
200MG 181 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    N-Phenylbenzylamine
  • Note
    Research use only, not for human use.
  • Brief Description
    A series of benzylaniline hydrochlorides as potential cytotoxic and antimitotic agents acting by inhibition of tubulin polymerization.
  • Description
    A series of benzylaniline hydrochlorides as potential cytotoxic and antimitotic agents acting by inhibition of tubulin polymerization.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cytoskeleton/Cell Adhesion Molecules
  • Target
    Microtubule/Tubulin
  • Recptor
    Tubulin polymerization
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    103-32-2
  • Formula Weight
    183.25
  • Molecular Formula
    C13H13N
  • Purity
    >98% (HPLC)
  • Solubility
    Limited solubility
  • SMILES
    C(NC1=CC=CC=C1)C1=CC=CC=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cushman M, et al. J Med Chem. 1993 Sep 17;36(19):2817-2
molnova catalog
related products
  • Auristatin F

    Auristatin F is an effective inhibitor of microtubule and vascular damaging agent. Auristatin F can be used in antibody-drug conjugates.

  • Thiabendazole

    Thiabendazole is an Antihelminthic. Hiabendazole is a benzimidazole compound that acts as a fungicide and is reported to have aneugenic effects.

  • TR-100

    TR-100 (TR100) is a specific anti-tropomyosin compound that disrupts the actin cytoskeleton via targeting of Tpm3.1-containing actin filaments.